Experiments

Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).

• A pan-cancer single-cell transcriptomic atlas of human bone metastases.

  PMID 41619722 · PMC12923970 · Cell reports. Medicine · 2026 · 8 claims · 8 setups

  Full-text index only

  Constructed a pan-cancer single-cell transcriptomic atlas of 62 human bone metastases (predominantly spinal) across 13 primary cancer types, with paired primary tumor and normal bone marrow samples.

  bone paired plasmacytoma malignant scrna-seq ihc infercnv

• Aryl Hydrocarbon Receptor Ligands Drive Pancreatic Cancer Initiation and Progression through Protumorigenic T-cell Polarization.

  PMID 40905825 · PMC12793834 · Cancer discovery · 2026 · 8 claims · 8 setups

  Full-text index only

  AHR ligands (cigarette smoke extract and TCDD) promote PDAC tumor growth in a syngeneic orthotopic mouse model

  pdac naïve il22 orthotopic naïve western

• Genomic biomarkers of immunotherapy plus chemotherapy in patients with advanced NSCLC: Insights from the phase 3 ORIENT-11 study.

  PMID 41660271 · PMC12876322 · iScience · 2026 · 8 claims · 8 setups

  Full-text index only

  A 9-gene Immune-Chemotherapy Prediction Score (ICPscore), derived from ORIENT-11 via WGCNA and LASSO Cox regression, predicts survival benefit from ICI plus chemotherapy in advanced NSCLC

  orient-11 hub nsclc oak bulk pd-l1 wgcna

• CLK1 Promotes Myeloid-Derived Suppressor Cell Trafficking and Reprograms the Tumor Microenvironment by Activating Hippo/YAP Signaling in Colorectal Cancer.

  PMID 41686262 · PMC13136879 · Cancer immunology research · 2026 · 8 claims · 8 setups

  Full-text index only

  CLK1 is markedly upregulated in immune-cold colorectal tumors and correlates with increased MDSC infiltration and CD8+ T-cell exclusion

  colorectal tcga-coad ct26 tumor scrna-seq bulk multiplex

• Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104).

  PMID 38897205 · PMC11293361 · Cell reports. Medicine · 2024 · 8 claims · 8 setups

  Has reproduction · 72

  Neoadjuvant sintilimab plus carboplatin/nab-paclitaxel is clinically feasible and tolerable in resectable EGFR-mutant NSCLC, with all 18 patients completing treatment and undergoing radical surgery.

  pre resected tumor serial whole-exome bulk single-cell

• Genomic and Immune Landscape of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Progressing on Anti-PD-1 Treatment.

  PMID 41666253 · PMC13044521 · Cancer immunology research · 2026 · 6 claims · 8 setups

  Full-text index only

  Tumor biopsies from anti-PD-1-resistant SCCHN show significantly more EGFR and MYCL amplifications and increased MYC pathway alterations compared with anti-PD-1-naive tumors

  ffpe blood tumor whole-exome bulk multiplex

• VISTA drives pancreatic tumor progression through modulation of the tumor-associated macrophage polarity.

  PMID 41776161 · PMC13194722 · Nature communications · 2026 · 8 claims · 8 setups

  Full-text index only

  VISTA deficiency significantly impairs PDAC tumor growth and prolongs survival in murine orthotopic models

  pan02 cd45+ tumor mice orthotopic pharmacological flow

• CCL3+ Neutrophil Signature Predicts Response to Neoadjuvant Toripalimab plus Chemotherapy in Patients with Hypopharyngeal Squamous Cell Carcinoma: A Phase II Trial.

  PMID 41817286 · PMC13223550 · Clinical cancer research : an official journal of the American Association for Cancer Research · 2026 · 7 claims · 8 setups

  Full-text index only

  A proinflammatory, CCL3-high neutrophil subset (Neu_CCL3) is significantly enriched in the pretreatment tumor microenvironment of patients who respond to nCIT.

  pretreatment microarray cohorts moc1 single-cell bulk immunohistochemistry

• PBRM1 Deficiency Reshapes an Immune Suppressive Microenvironment Through Epigenetic Tuning of PBRM1-KDM5C-IL6 Axis in ccRCC.

  PMID 41514194 · PMC13042695 · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026 · 8 claims · 8 setups

  Full-text index only

  PBRM1 deficiency increases infiltration of immunosuppressive M2 tumor-associated macrophages (TAMs) and creates an immune-excluded tumor microenvironment

  vhl kidney pbrm1 immunodeficient scrna-seq multiplex crispr-cas9

• Anti-CSF-1R therapy with combined immuno-chemotherapy coordinate an adaptive immune response to eliminate macrophage enriched triple negative breast cancers.

  PMID 41484081 · PMC12858953 · Nature communications · 2026 · 8 claims · 8 setups

  Full-text index only

  Combined low-dose CTX + anti-CSF-1R (SNDX-ms6352) is highly effective against aggressive metastatic Trp53-null TNBC models with high macrophage infiltration, producing complete tumor regression in claudin-low models.

  trp53-null complete t12 cell-deficient imaging survival tumor